ACADEMIA

Linguagen Corp., a leader in the identification and development of new compounds to improve the taste of pharmaceutical, food and beverage products, announces the appointment of Joseph A. Mollica, Ph.D., to its Board of Directors. Dr. Mollica currently serves as Chairman of Pharmacopeia Drug Discovery, Inc., a drug discovery company. "Dr. Mollica's extensive operational and management experience in both the pharmaceutical and biotechnology sectors makes him an exceptional addition to our Board of Directors," said Ray Salemme, Ph.D., CEO of Linguagen Corp. "As Linguagen continues to grow, we will look to Dr. Mollica to lend his expertise to help us develop our strategy and foster new relationships with business partners and investors." >From 1994 to 2004, Dr. Mollica served as Chairman, President and CEO of Pharmacopeia, Inc., a N.J.-based drug discovery and software technology company. Pharmacopoeia Inc. consisted of the Pharmacopoeia Drug Discovery Division and Accelrys, a software division providing computational modeling and simulation software for cheminformatics and bioinformatics to the pharmaceutical and chemical industries. From 1987 to December 1993, Dr. Mollica was employed by The DuPont Company, initially as Vice President, Medical Products for Dupont, and from 1991 to 1993 as President and Chief Executive Officer of the DuPont Merck Pharmaceutical Company. Earlier in his career, Dr. Mollica was a senior chemist at Ciba-Geigy rising to Senior Vice President of the company's Pharmaceutical Division. Dr. Mollica also serves on the Boards of Genencor International Inc. and Neurocrine Biosciences. In 1999, Dr. Mollica was inducted into the New Jersey High-Tech Hall of Fame in the high-tech business leaders category. He received his B.S. from the University of Rhode Island and M.S. and Ph.D. degrees from the University of Wisconsin and an Sc.D., h.c. from the University of Rhode Island.